Company news
Jw (cayman) Therapeutics Co. Ltd. (HKEX:2126) news
Jw (cayman) Therapeutics Co. Ltd. news releases on 6ix. Latest, Oct 31, 2025: JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement…
Press releases & updates
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential
October 31, 2025
JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao
June 3, 2025
JW Therapeutics - Receipt of Breakthrough Therapy Designation for Carteyva in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma
January 13, 2025
JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma
July 4, 2022
JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma
March 31, 2022
JW Cayman Therapeutics : Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China
September 6, 2021
JW Therapeutics : Announces Strategic Partnership with MediTrust Health
August 20, 2021
JW Cayman Therapeutics : CHANGE OF COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT
July 30, 2021
JW Cayman Therapeutics : PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND RE-ELECTION OF RETIRING DIRECTORS AND RE-APPOINTMENT OF AUDITOR AND NOTICE OF ANNUAL GENERAL MEETING
April 23, 2021
JW Cayman Therapeutics : VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE SHARES OF THE COMPANY IN THE HONG KONG STOCK CONNECT LIST UNDER THE SHENZHEN-HONG KONG STOCK CONNECT
March 15, 2021